
 
 
 
 
 
 
 
 
  [CLAIMS] 
 
  [Claim 1 ]  
  A polypeptide comprising one amino acid sequence, or a combination of two or more amino acid sequences, selected from the group consisting of SEQ ID NOs: 109 to 1 14.  
 
 
  [Claim 2]  
  The polypeptide according to Claim 1 comprising  
  the amino acid sequence of SEQ ID NO: 1 15 or SEQ ID NO: 1 17;  
  the amino acid sequence of SEQ ID NO: 1 16 or SEQ ID NO: 1 18; or  
  a combination thereof.  
 
 
  [Claim 3 ]  
  An anti-EGFR antibody or an antigen-binding fragment thereof, comprising: at least one heavy chain complementarity determining region selected from the group consisting of a CDR-Hl comprising the amino acid sequence of SEQ ID NO: 109, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 1 10, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 1 1 1 ; and  
  at least one light chain complementarity determining region selected from the group consisting of CDR-L1 comprising the amino acid sequence of SEQ ID NO: 1 12, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 1 13, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 1 14.  
 
 
  [Claim 4]  
  The anti-EGFR antibody or the antigen-binding fragment according to Claim 3, comprising:  
  a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 15 or SEQ ID NO: 1 17, and  
  a light chain variable region comprising the amino acid sequence of SEQ ID NO: 1 16 or SEQ ID NO: 1 18;  
 
 
  [Claim 5]  
  The anti-EGFR antibody or the antigen-binding fragment according to Claim 3, wherein the anti-EGFR antibody or the antigen-binding fragment is in an anti-EGFR scFv 

 form.  
 
 
  [Claim 6]  
  An anti-c-Met/anti-EGFR bispecific antibody comprising an anti-c-Met antibody or an antigen-binding fragment thereof and an anti-EGFR antibody or an antigen-binding fragment thereof, wherein  
  (i) the anti-c-Met antibody or antigen-binding fragment thereof binds to an epitope comprising 5 or more contiguous amino acids of SEQ ID NO: 79; and  
  (ii) the anti-EGFR antibody or antigen-binding fragment thereof comprises:  
  at least one heavy chain complementarity determining region selected from the group consisting of a CDR-Hl comprising the amino acid sequence of SEQ ID NO: 109, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 1 10, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 1 1 1 ; and  
  at least one light chain complementarity determining region selected from the group consisting of a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 1 12, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 1 13, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 1 14.  
 
 
  [Claim 7]  
  The anti-c-Met/anti-EGFR bispecific antibody according to Claim 6, wherein the antigen-binding fragment of the anti-c-Met antibody or the antigen-binding fragment of the anti-EGFR antibody is independently selected from the group consisting of scFv, (scFv)2, scFvFc, Fab, Fab', and F(ab')2.  
 
 
  [Claim 8]  
  The anti-c-Met/anti-EGFR bispecific antibody according to Claim 6, wherein the anti-c-Met antibody or the antigen-binding fragment thereof binds to an epitope having 5 to 19 contiguous amino acids of SEQ ID NO: 71 , and the epitope comprises the amino acid sequence of SEQ ID NO: 73.  
 
 
  [Claim 9]  
  The anti-c-Met/anti-EGFR bispecific antibody according to Claim 8, wherein the anti-c-Met antibody or the antigen-binding fragment thereof comprises:  
  at least one heavy chain complementarity determining region selected from the 

 group consisting of (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 4; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 5, SEQ ID NO: 2, or an amino acid sequence comprising 8-19 consecutive amino acids within SEQ ID NO: 2 including the amino acid residues from the 3 rd  to 10 th  positions of SEQ ID NO: 2; and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 6, SEQ ID NO: 85, or an amino acid sequence comprising 6-13 consecutive amino acids within SEQ ID NO: 85 including the amino acid residues from the 1 st  to 6 th  positions of SEQ ID NO: 85; and  
  at least one light chain complementarity determining region (CDR) selected from the group consisting of (a) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 7, (b) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 8, and (c) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 9, SEQ ID NO: 86, or an amino acid sequence comprising 9-17 consecutive amino acids within SEQ ID NO: 89 including the amino acid residues from the 1 st  to 9 th  positions of SEQ ID NO: 89.  
 
 
 [Claim 10]  
  The anti-c-Met/anti-EGFR bispecific antibody according to Claim 9, wherein the CDR-H1 of the anti-c-Met antibody or antigen binding fragment thereof comprises the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 22, SEQ ID NO: 23, or SEQ ID NO: 24,  
  the CDR-H2 of the anti-c-Met antibody or antigen binding fragment thereof comprises the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 25, or SEQ ID NO: 26,  
  the CDR-H3 of the anti-c-Met antibody or antigen binding fragment thereof comprises the amino acid sequence of SEQ ID NO: 3, SEQ ID NO: 27, SEQ ID NO: 28, or SEQ ID NO: 85,  
  the CDR-L1 of the anti-c-Met antibody or antigen binding fragment thereof comprises the amino acid sequence of SEQ ID NO: 10, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31 , SEQ ID NO: 32, SEQ ID NO: 33, or SEQ ID NO: 106,  
  the CDR-L2 of the anti-c-Met antibody or antigen binding fragment thereof comprises the amino acid sequence of SEQ ID NO: 11, SEQ ID NO: 34, SEQ ID NO: 35, 

 or SEQ ID NO: 36, and  
  the CDR-L3 of the anti-c-Met antibody or antigen binding fragment thereof comprises the amino acid sequence of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 37, SEQ ID NO: 86, or SEQ ID NO: 89.  
 
 
 [Claim 1 1 ]  
  The anti-c-Met/anti-EGFR bispecific antibody according to Claim 9, wherein the anti-c-Met antibody or the antigen-binding fragment thereof comprises:  
  a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 17, 74, 87, 90, 91 , 92, 93, or 94, and  
  a light chain variable region comprising the amino acid sequence of SEQ ID NO: 18, 19, 20, 21, 75, 88, 95, 96, 97, 98, 99, or 107.  
 
 
  [Claim 121  
  The anti-c-Met/anti-EGFR bispecific antibody according to Claim 9, wherein the anti-c-Met antibody comprises:  
  a heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 62, the amino acid sequence from the 18 th  to 462 nd  positions of SEQ ID NO: 62, SEQ ID NO: 64, the amino acid sequence from the 18 th  to 461 st  positions of SEQ ID NO: 64, SEQ ID NO: 66, and the amino acid sequence from the 18 th  to 460 th  positions of SEQ ID NO: 66; and  
  a light chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 68, the amino acid sequence from the 21 st  to 240 th  positions of SEQ ID NO: 68, SEQ ID NO: 70, the amino acid sequence from the 21 st  to 240 th  positions of SEQ ID NO: 70, and SEQ ID NO: 108.  
 
 
  [Claim 13 ]  
  The anti-c-Met/anti-EGFR bispecific antibody according to Claim 6, wherein the anti-EGFR antibody or the antigen-binding fragment thereof comprises:  
  a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 15 or SEQ ID NO: 1 17, and  
  a light chain variable region comprising the amino acid sequence ' of SEQ ID NO: 1 16 or SEQ ID NO: 1 18. 

  
 
 
 [Claim 14]  
  The anti-c-Met/anti-EGFR bispecific antibody according to any one of Claims 6 to 13, wherein the anti-EGFR antibody or the antigen-binding fragment thereof is linked to C-terminus of the anti-c-Met antibody.  
 
 
  [Claim 15 ]  
  A pharmaceutical composition for preventing or treating a cancer comprising the anti-EGFR antibody or the antigen-binding fragment thereof of any one of Claims 3 to 5, or the anti-c-Met/anti-EGFR bispecific antibody of any one of Claims 6 to 13.  
 
 
  [Claim 16]  
  A nucleic acid encoding the polypeptide of Claim 1 or 2, the anti-EGFR antibody or the antigen -binding fragment thereof of any one of Claims 3 to 5, or the anti-c- Met/anti-EGFR bispecific antibody of any one of Claims 6 to 13.  
 
 
  [Claim 17]  
  A method of producing the polypeptide of Claim 1 or 2, the anti-EGFR antibody or the antigen-binding fragment thereof of any one of Claims 3 to 5, or the anti-c- Met/anti-EGFR bispecific antibody of any one of Claims 6 to 13, comprising expressing a nucleic acid encoding the antibody or antigen-binding fragment in a cell. 
 
 
 
 
 
 
 
 
 
 
 
